BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final hospital outpatient payment rates for its breakthrough SAINT® neuromodulation therapy. This important ruling significantly expands access to SAINT therapy for Medicare patients with treatment-resistant major depressive disorder (TR-MDD) in the hospital outpatient setting.
In the finalized ruling, CMS assigned the SAINT treatment day CPT Category III codes to New Technology APC 1525, with a national average payment rate of $3,750.50 per day. Additionally, CMS reaffirmed New Technology APC 1511 for SAINT Targeting with a national average payment of $950. Beginning on Jan 1, 2025, hospitals will receive $19,703.00 for the complete SAINT therapy protocol, ensuring that the resources required to deliver the precise, individualized treatment are available.
“The decision by CMS marks a major milestone for the treatment of those who suffer from treatment-resistant depression. It also reflects the growing body of clinical evidence supporting the use of SAINT therapy as a potentially lifesaving treatment,” said Christian Gormsen, president and CEO of Magnus Medical. “By streamlining access and payment for SAINT therapy in hospital outpatient settings, we’re empowering more providers to offer this innovative, life-changing treatment to people who desperately need it.”
“As a psychiatrist specializing in neuropsychiatric disorders, I’ve witnessed firsthand the suffering and debilitating effects of treatment-resistant depression. For many people, traditional treatments don’t always prove effective,” said Baron Short, M.D., MSCR, medical director, Brain Stimulation Service at MUSC Health. “With this new CMS rule, SAINT therapy will be accessible to a wider range of patients, potentially changing lives of those who have previously been unable to find relief from their intractable depression.”
Treatment-resistant MDD is a condition that impacts over 50% of people with depression who don’t respond to medications and psychotherapy.1 Treatment with SAINT changes a person’s brain circuitry to treat MDD more effectively by precisely targeting the underlying neural circuitry responsible for depression.
Specifically, SAINT therapy works by leveraging structural and functional magnetic resonance imaging (MRI) scans to inform a proprietary algorithm that pinpoints the optimal anatomical target for precise neurostimulation in individuals with major depression. The groundbreaking treatment is performed on an accelerated, five-day timeline, minimizing disruption to people’s lives.
About Magnus
Magnus Medical, Inc., is a privately held therapeutic neuromodulation company driven to transform lives by restoring mental health. Co-founded in 2020, the company’s first product is the SAINT neuromodulation system, which provides a new form of individualized neurostimulation for treatment-resistant depression indicated for adults who have failed to achieve satisfactory improvement from prior antidepressant medications. For more information, visit https://www.magnusmed.com.
